Takeda has received approval from the National Institute for Health and Care Excellence (NICE) for the manufacture of a new drug, Entyvio (vedolizumab), designed to treat ulcerative colitis.
Approximately 146,000 people in the UK are currently living with ulcerative colitis, which causes severe inflammation of the large intestine and results in painful digestive issues.
Current treatments available for the condition are not deemed very effective, but Takeda says that vedolizumab can help to lessen the condition’s symptoms.
The drug specifically targets the immune system in the gut, leaving the rest of the body’s biological defences unaffected.
Chris Probert, vice-chair of the Clinical Advisers Committee for Crohn’s and Colitis UK and professor of gastroenterology at the University of Liverpool, said: “For our patients, achieving long-lasting remission with minimal side effects is the goal of treatment and this has been proven in clinical trials for vedolizumab.”